Cipla has announced further investment of up to Rs 26 crore in Achira Labs, a company specializing in point-of-care medical test kits. This...

Cipla's volatile journey from a 52-week high to a support level. Using Debit Spread strategy, Madhu Bansal advises on call options. Exit by...

Yusuf Hamied and Mustafa Hamied, promoters of Cipla, are selling as much as a 2.5% stake in the drugmaker through a block deal on Tuesday t...

Drug major Cipla is exploring all legal options in the wake of Delhi High Court's ruling that it has infringed Swiss drug major Hoffman-La ...

Cipla today reported an over two-fold jump in its consolidated net profit to Rs 650.61 crore for the quarter ended June 30, 2015 mainly on ...

At 09:40 a.m.; Cipla was trading 2.4 per cent higher at Rs 742.20. It hit a low of Rs 725 and a high of Rs 744.90 in trade today.

From a valuation perspective specifically from an FY16 perspective our belief is Cipla around 24.5 times-25 times forward earnings seems to...

They have already been re-rated a lot so I guess there is little scope at least in the longer term perspective for that to happen

Drug major Cipla said it has launched biosimilar of Etanercept under the brand name 'Etacept' used for treatment of rheumatic disorders in ...

Cipla Medpro is a South African affiliate of Cipla. The companies enjoy a long-standing business relationship spanning two decades.

India’s second largest drug company Cipla has launched Qvir, a combination of four HIV drugs in one single strip.

Drug major Cipla today said it has launched 'Qvir', a four-drug kit priced at Rs 158 per kit to be used for treating HIV/AIDS.

Drug firm Cipla today said it has lost an appeal in a US court over a patent case against Merial Ltd regarding an animal healthcare product.

Indian generics drug maker Cipla has raised $140 million (nearly Rs 671 crore) through a qualified institutional placement (QIP) of shares ...

South African company Adcock Ingram's plans to buy Cipla Medpro, with whom Cipla has a 20-year drug-supply agreement, has run into trouble ...

Indian drug major Cipla and private equity (PE) funds are working out an innovative financing model to bid for Merck’s generic business.

Drug major Cipla is exploring the option of joining a consortium of private equity firms in bidding for the generics business of German dru...